STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$2.00 USD
-0.09 (-4.31%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LAB 2.00 -0.09(-4.31%)
Will LAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LAB
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
5 Medical Info Systems Stock to Buy for a Stable Portfolio
LAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LAB
Standard BioTools (LAB) Receives a Buy from TD Cowen
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update
Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying